PMID- 33067822
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1099-1344 (Electronic)
IS  - 0362-4803 (Linking)
VI  - 64
IP  - 1
DP  - 2021 Jan
TI  - Production of the next-generation positron nuclide zirconium-89 ((89) Zr) guided 
      by Monte Carlo simulation and its good quality for antibody labeling.
PG  - 47-56
LID - 10.1002/jlcr.3888 [doi]
AB  - The next-generation positron zirconium-89 ((89) Zr, T(1/2) = 3.27 days) is a 
      novel nuclide for immunological positron emission tomography because of its 
      favorite longer half-life. The aim of this work is to develop optimized methods 
      for routine production and purification of (89) Zr through Monte Carlo (MC) 
      simulation and laboratory experiments. (89) Y(p,n)(89) Zr reaction was used for 
      (89) Zr production. Optimized thicknesses of Al degrader (0.11 cm) and (89) Y 
      foil (0.064 cm) were simulated through MC method. (89) Zr (15.0-40.7 mCi) with an 
      average production rate of 0.92 +/- 0.12 mCi/muA.h was produced after 1- to 2-h 
      bombardment at the proton beam energy of 20 MeV and current of 20 muA. High 
      radio-purity (89) Zr (6.14-26.8 mCi) obtained eluted from hydroxamate resin using 
      1-mol/L oxalic acid solution, with the concentration of 2.7 x 10(4) mCi/L. The 
      gamma spectrum showed that the characteristic peak of (89) Zr was 511 and 909 
      keV, and no impurities were found. [(89) Zr]Zr-DFO-trastuzumab was successfully 
      labeled and performed good radiochemical purity (>95%) and stability that showed 
      potential application in tumor molecular imaging.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Wang, Feng
AU  - Wang F
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Nuclear Medicine, Peking University Cancer 
      Hospital & Institute, Beijing, China.
FAU - Ding, Jin
AU  - Ding J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Nuclear Medicine, Peking University Cancer 
      Hospital & Institute, Beijing, China.
FAU - Guo, Xiaoyi
AU  - Guo X
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Nuclear Medicine, Peking University Cancer 
      Hospital & Institute, Beijing, China.
FAU - Liu, Teli
AU  - Liu T
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Nuclear Medicine, Peking University Cancer 
      Hospital & Institute, Beijing, China.
FAU - Ding, Lixin
AU  - Ding L
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Nuclear Medicine, Peking University Cancer 
      Hospital & Institute, Beijing, China.
FAU - Xia, Lei
AU  - Xia L
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Nuclear Medicine, Peking University Cancer 
      Hospital & Institute, Beijing, China.
FAU - Zhu, Hua
AU  - Zhu H
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Nuclear Medicine, Peking University Cancer 
      Hospital & Institute, Beijing, China.
FAU - Yang, Zhi
AU  - Yang Z
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Nuclear Medicine, Peking University Cancer 
      Hospital & Institute, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201030
PL  - England
TA  - J Labelled Comp Radiopharm
JT  - Journal of labelled compounds & radiopharmaceuticals
JID - 7610510
RN  - 0 (Radioisotopes)
RN  - C6V6S92N3C (Zirconium)
RN  - NTM296JU95 (Zirconium-89)
SB  - IM
MH  - Electrons
MH  - *Monte Carlo Method
MH  - *Radioisotopes
MH  - *Zirconium
OTO - NOTNLM
OT  - Monte Carlo
OT  - antibody
OT  - cyclotron
OT  - immuno-PET
OT  - positron emission tomography
OT  - solid target
OT  - zirconium-89
EDAT- 2020/10/18 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/10/17 05:31
PHST- 2020/09/01 00:00 [received]
PHST- 2020/09/28 00:00 [revised]
PHST- 2020/10/07 00:00 [accepted]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/10/17 05:31 [entrez]
AID - 10.1002/jlcr.3888 [doi]
PST - ppublish
SO  - J Labelled Comp Radiopharm. 2021 Jan;64(1):47-56. doi: 10.1002/jlcr.3888. Epub 
      2020 Oct 30.